Advanced search options

Advanced Search Options 🞨

Browse by author name (“Author name starts with…”).

Find ETDs with:

in
/  
in
/  
in
/  
in

Written in Published in Earliest date Latest date

Sorted by

Results per page:

You searched for subject:(SNX5422). One record found.

Search Limiters

Last 2 Years | English Only

No search limiters apply to these results.

▼ Search Limiters


University of Illinois – Chicago

1. Jose Antonio Suarez Del Pino (7974863). Development of Polymeric-Drug Conjugates for Delivering the HSP90 Inhibitor SNX5422.

Degree: 2017, University of Illinois – Chicago

Heat shock protein 90 (HSP90) inhibition has been considered as a potential treatment option for prostate cancer. However, several HSP90 inhibitors including SNX5422 were removed from cancer clinical trials due to visual toxicities. Recent animal studies showed retinal damage produced by HSP90 inhibitors and suggested a relationship between the plasma/eye ratio of the inhibitor and the retinal damage produced. The blood ocular barrier is known to be an obstacle for large molecules like polymers. Therefore, a polymer-HSP90 inhibitor conjugate could restrict the access to the eye of the inhibitor achieving a higher plasma/eye ratio than the free HSP90 inhibitor. The purpose of this study was to develop a PEG-SNX5422 conjugate through a dendritic structure (EDTA) to allow the incorporation up to 3 SNX5422 molecules per PEG chain. The system includes Cathepsin B degradable linkers for enzymatically triggered release of the drug. We synthesized several PEG-SNX5422 conjugates with different PEG lengths (5k to 20k) and different number of SNX5422 molecules attached to the polymer chain. The conjugates where submitted to an optimization process testing their in vitro characteristics: all the conjugates were stable in different buffers, including serum proteins, and able to release SNX5422 in the presence of the enzyme Cathepsin B. We observed a relationship between water solubility and growth inhibition properties of the conjugates against 2 different prostate cancer cell lines. PEG20k conjugates had the highest stability, water solubility and cytotoxic activity against prostate cancer cells, therefore it was selected for in vivo testing using a mouse model. PEG20k-SNX3 conjugates showed a significantly higher plasma/eye ratio than the free drug, suggesting that these conjugates can modify the biodistribution of SNX5422 and reduce its visual toxicities.

Subjects/Keywords: Uncategorized; HSP90; SNX5422; Polymer-Drug Conjugates; PEG; prostate cancer

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

(7974863), J. A. S. D. P. (2017). Development of Polymeric-Drug Conjugates for Delivering the HSP90 Inhibitor SNX5422. (Thesis). University of Illinois – Chicago. Retrieved from http://hdl.handle.net/10027/22198

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

(7974863), Jose Antonio Suarez Del Pino. “Development of Polymeric-Drug Conjugates for Delivering the HSP90 Inhibitor SNX5422.” 2017. Thesis, University of Illinois – Chicago. Accessed May 08, 2021. http://hdl.handle.net/10027/22198.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

(7974863), Jose Antonio Suarez Del Pino. “Development of Polymeric-Drug Conjugates for Delivering the HSP90 Inhibitor SNX5422.” 2017. Web. 08 May 2021.

Vancouver:

(7974863) JASDP. Development of Polymeric-Drug Conjugates for Delivering the HSP90 Inhibitor SNX5422. [Internet] [Thesis]. University of Illinois – Chicago; 2017. [cited 2021 May 08]. Available from: http://hdl.handle.net/10027/22198.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

(7974863) JASDP. Development of Polymeric-Drug Conjugates for Delivering the HSP90 Inhibitor SNX5422. [Thesis]. University of Illinois – Chicago; 2017. Available from: http://hdl.handle.net/10027/22198

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

.